J.P. Morgan Maintains OW Rating on Hospira Following Management Meeting

J.P. Morgan recently met with Hospira's HSP management team “and wanted to share our quick takeaways and highlights from the discussion.” “Specifically, we remain upbeat about generic Taxotere dynamics and comfortable with our above guidance forecast of $4.05 for 2011 EPS,” J.P. Morgan writes. “Beyond Taxotere, we see several of the overhangs that impacted the company's results in 2010 (manufacturing warning letters, Plum and Symbiq challenges) lifting as we move through the next 9-12 months, and we are maintaining our Overweight rating.” Hospira closed Wednesday at $54.89.